Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.44 |
| ▸ | GRK6 | P43250 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31672310 | 1.00 | TSHR (0.60) | TSHRCYP3A4ALDH1A1MAPTGPR35 | |
| SCHEMBL4966586 | 0.86 | TSHR (0.56) | TSHRCYP3A4ALDH1A1MAPTGPR35 | |
| SCHEMBL20362277 | 0.85 | TSHR (0.46) | TSHRCYP3A4ALDH1A1MAPT | |
| SCHEMBL95377 | 0.85 | TSHR (0.60) | TSHRCYP3A4ALDH1A1MAPTGPR35 | |
| SCHEMBL7193090 | 0.85 | TSHR (0.64) | TSHRCYP3A4ALDH1A1MAPTGPR35 | |
| SCHEMBL27599498 | 0.83 | TSHR (0.62) | TSHRCYP3A4ALDH1A1MAPTGPR35 | |
| SCHEMBL6907821 | 0.81 | TSHR (0.60) | TSHRCYP3A4ALDH1A1GPR35KAT2B | |
| SCHEMBL29137475 | 0.81 | TSHR (0.60) | TSHRCYP3A4ALDH1A1MAPTGPR35 | |
| SCHEMBL68365 | 0.81 | TSHR (0.60) | TSHRCYP3A4ALDH1A1MAPTGPR35 | |
| SCHEMBL16976285 | 0.81 | TSHR (0.60) | TSHRCYP3A4ALDH1A1MAPTGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400166-A2 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| EP-3565484-B1 | COMPOSITIONS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | CONTRALINE INC (US) | 2024-04-03 | — | — | EP | claimed |
| CN-110835361-A | Sialic acid glycosyl donor and preparation method and application thereof | 山东大学 | 2020-02-25 | — | — | CN | claimed |
| EP-3565484-A1 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. (US) | 2019-11-13 | — | — | EP | claimed |
| WO-2018129369-A1 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. (US) | 2018-07-12 | — | — | WO | claimed |
| US-20180185096-A1 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. | 2018-07-05 | — | — | US | claimed |
| US-12383421-B2 | Contraceptive devices | Contraline, Inc. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-115066428-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-12275686-B2 | NO donor compound, preparation method thereof, pharmaceutical composition comprising same, and use thereof | SOUTHEAST UNIVERSITY (CN) | 2025-04-15 | — | — | US | disclosed |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2025-04-10 | — | — | US | disclosed |
| CN-116675620-B | NO donor compound, preparation method, pharmaceutical composition and application thereof | 东南大学 | 2025-01-10 | — | — | CN | disclosed |
| EP-4484409-A1 | NO DONOR COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Southeast University (CN) | 2025-01-01 | — | — | EP | disclosed |
| US-20240409500-A1 | NO DONOR COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | SOUTHEAST UNIVERSITY (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-0278452-B1 | 2,4- and 2,5-Pyridine-dicarboxylic-acid derivatives, process for their preparation, their use and medicines based on these compounds | HOECHST AG (DE) | 1995-05-24 | — | — | EP | disclosed |
| US-5387684-A | For treatment and prophylaxis of angiotensin II-mediated diseases such as circulatory diseases of hypertension and heart failure | THE GREEN CROSS CORPORATION (JP) | 1995-02-07 | — | — | US | disclosed |
| EP-0627434-A1 | Tricyclic quinoxalinedione derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-12-07 | — | — | EP | disclosed |
| US-5364873-A | Influencing metabolism of collagen | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-15 | — | — | US | disclosed |
| EP-0602246-A1 | ISOINDAZOLE COMPOUND | THE GREEN CROSS CORPORATION (JP) | 1994-06-22 | — | — | EP | disclosed |
| US-5238948-A | Influence metabolism of collagen or biosynthesis of C1q | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-24 | — | — | US | disclosed |
| EP-0278452-A2 | 2,4- and 2,5-Pyridine-dicarboxylic-acid derivatives, process for their preparation, their use and medicines based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | CKS1B, CSNK1A1, CKS2 | TSHR 4057/4885CYP3A4 1635/4885ALDH1A1 539/4885 |
| US-12275686-B2 | NO donor compound, preparation method thereof, pharmaceutical composition comprising same, and use thereof | HIF1A, NOS1, NOS2 | TSHR 4509/4885CYP3A4 287/4885ALDH1A1 497/4885 |
| US-20240409500-A1 | NO DONOR COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | HIF1A, NOS1, NOS2 | TSHR 4509/4885CYP3A4 287/4885ALDH1A1 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.